Product

Company

NCT00646932·10 sites·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Abbott

The purpose of this study is pharmacokinetic \& tolerability.

Age

20–74

Sex

ALL

Healthy volunteers

Not accepted

Subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure

Subject is considered by investigator, for any reason, to be an unsuitable candidate for the study

The record

StatusCompleted

PhasePhase 2

Taking part25

StartedNov 2005

UpdatedMar 31, 2008

Conditions

Where10

Clareo Health | Paricalcitol Injection Phase II Trial